There were three novel small molecules approved in May 2022:
- vonoprazan (Voquezna): a potassium-competitive acid blocker (PCAB)
- tapinarof (Vtama): an aryl hydrocarbon receptor (AhR) agonist
- tirzepatide (Mounjaro): a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins.
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.
